Therefore, we propose that NSCLC cells maintain elevated lncCDH5-3:3 expression for a certain time during carcinogenesis, and in cancer cells with specific mutations, for example, in KRAS or p53, such as in A549 or H1703 cells, respectively. This evidence concerns the gene KRAS and non-small cell lung carcinoma.